Meeting
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
Authors
Jessica Hochberg
New York Medical College, Valhalla, NY
Jessica Hochberg , Javier E. Oesterheld , Allyson Flower , Liana Klejmont , Jaclyn Basso , Lauren Harrison , Qiuhu Shi , Michael J. Borowitz , Michael Loken , Mitchell S. Cairo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01842672
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7036)
DOI
10.1200/JCO.2019.37.15_suppl.7036
Abstract #
7036
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia.
First Author: Jessica Hochberg
Poster
2011 ASCO Annual Meeting
Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia.
First Author: P. Kearns
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2021 ASCO Annual Meeting
Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.
First Author: Ritul Sharma